Report copyright - Dossier zur Nutzenbewertung gemäß § 35a SGB V · 2020. 7. 22. · PI Proteaseinhibitor PIB Pibrentasvir PTV Paritaprevir RBV Ribavirin RNA Ribonukleinsäure RR Relatives Risiko
Please pass captcha verification before submit form
Please pass captcha verification before submit form